Welcome to Markets Desk, here's what's moving.
Grab's chief operating officer has sold roughly one hundred forty-five thousand company shares at three dollars and forty-eight cents each, pulling in about five hundred six thousand dollars. The move comes after the Southeast Asian super-app's stock has shed twenty-eight percent over the past year, and insider selling at depressed levels tends to raise eyebrows on the floor.
Shifting to healthcare, Guardant Health is getting a meaningful lift after the FDA approved its Guardant three-sixty CDx as a companion diagnostic for ESR one-mutated breast cancer. The liquid biopsy test will now help identify hormone receptor-positive, HER two-negative metastatic patients eligible for targeted treatment, expanding Guardant's commercial footprint in oncology diagnostics considerably.
And in the quantum computing space, Rigetti Computing continues to attract long-term speculation, though the company's own management acknowledges commercial revenue remains in its earliest stages. Investors betting on a three-year horizon are essentially wagering on infrastructure buildout and enterprise adoption timelines that remain genuinely uncertain at this point.
That's the tape. Markets Desk, signing off the floor.
